GSTM1 and anemia (phenotype): To test the value of this proposed alternative dosing practice, we conducted the REALISE open-label, single-arm, phase 2 study that evaluated the efficacy and safety of a novel dosing strategy of ruxolitinib, consisting of a reduced starting dose (10 mg b.i.d.)with delayed up-titration in patients with MF and anemia (Hb <10 g/dl) [26].